Free tool
FAERS Monitor: Abrilada
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761118 or its brand name (Abrilada, Adalimumab-Afzb). Reports on generic versions are filed under their own applications.
Reports
2,683
Serious
2,295
86% of reports
Hospitalization
486
Death reported
123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use824
- condition aggravated636
- drug ineffective346
- fatigue262
- arthralgia229
- pain198
- injection site pain173
- drug dose omission by device145
- nausea142
- abdominal pain139
- diarrhoea135
- headache129
- inappropriate schedule of product administration126
- device mechanical issue122
- malaise117
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 340 |
| 2023 | 752 |
| 2024 | 794 |
| 2025 | 570 |
| 2026 | 223 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,476 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device mechanical issueSignal | 122 | 70.4 | 59.1 | 8,206 |
| condition aggravatedSignal | 636 | 16.4 | 15.4 | 9,317 |
| drug dose omission by deviceSignal | 145 | 14.5 | 12.4 | 1,818 |
| off label useSignal | 824 | 7.4 | 7.0 | 4,734 |
| inappropriate schedule of product administrationSignal | 126 | 5.5 | 4.6 | 461 |
| abdominal painSignal | 139 | 4.7 | 4.0 | 404 |
| injection site painSignal | 173 | 4.4 | 3.8 | 461 |
| arthralgiaSignal | 229 | 4.3 | 3.8 | 592 |
| fatigueSignal | 262 | 2.6 | 2.4 | 275 |
| painSignal | 198 | 2.5 | 2.2 | 187 |
| malaiseSignal | 117 | 2.1 | 1.8 | 67 |
| drug ineffectiveSignal | 346 | 2.1 | 1.9 | 200 |
| diarrhoea | 135 | 1.6 | 1.4 | 34 |
| headache | 129 | 1.6 | 1.4 | 30 |
| nausea | 142 | 1.4 | 1.2 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.